Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fenofibric acid (FNF acid) 是 fenofibrate 的活性代谢物,是PPAR 激动剂,对 PPARα、PPARγ 和 PPARδ 的EC50值分别为 22.4、1.47 和 1.06 µM。它抑制COX-2的活性,IC50值为 48 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 g | ¥ 331 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 274 | 现货 |
产品描述 | Fenofibric acid (FNF acid) is the active form of fenofibrate, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity. |
靶点活性 | COX-2:48 nM, PPARγ:1.47 µM(EC50), PPARα:22.4 µM(EC50), PPARδ:1.06 µM(EC50) |
体外活性 | Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR[1]. |
体内活性 | Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of Fenofibric acid on EPC mobilization in the OIR model is PPARα-dependent.Fenofibric acid Inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. Fenofibric acid decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina[1]. |
细胞实验 | PPAR activators fenofibric acid is dissolved in DMSO and added to the culture medium containing 0.2% BSA. RAW264 cells are washed with PBS and cultured an additional 48 hours in the presence of fenofibric acid in DMEM/F-12(1:1) medium containing 2% TCM and 0.2% BSA. During the last 24 hours of the drug treatment, 300 mol/L of dibutyryl cAMP and apoA-I (10 μg/mL) are added to the medium. THP-1 cells are also treated with the compound and apoA-I in 0.2% BSA-RPMI 1640 medium and 0.1% BSA-MEM. Cholesterol and choline-phospholipid released into the medium by apoA-I are determined enzymatically. Adherent cells are dissolved in 0.1 N NaOH for protein determination by bicinchoninic acid protein assay system. (Only for Reference) |
别名 | 非诺贝特酸, Trilipix, FNF acid, NSC 281318 |
分子量 | 318.75 |
分子式 | C17H15ClO4 |
CAS No. | 42017-89-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32 mg/mL (100.39 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1373 mL | 15.6863 mL | 31.3725 mL | 78.4314 mL |
5 mM | 0.6275 mL | 3.1373 mL | 6.2745 mL | 15.6863 mL | |
10 mM | 0.3137 mL | 1.5686 mL | 3.1373 mL | 7.8431 mL | |
20 mM | 0.1569 mL | 0.7843 mL | 1.5686 mL | 3.9216 mL | |
50 mM | 0.0627 mL | 0.3137 mL | 0.6275 mL | 1.5686 mL | |
100 mM | 0.0314 mL | 0.1569 mL | 0.3137 mL | 0.7843 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fenofibric acid 42017-89-0 DNA Damage/DNA Repair Immunology/Inflammation Metabolism Neuroscience Proteases/Proteasome MMP COX PPAR Peroxisome proliferator-activated receptors Inhibitor inhibit NSC-281318 非诺贝特酸 Cyclooxygenase Trilipix FNF acid NSC 281318 NSC281318 inhibitor